Credit: Sergeyryzhov/Getty Images
Mabion, a CDMO based in Poland, launched a €500,000 ($574,000) oncology services contest at the BIO International Convention aimed at accelerating the development of recombinant protein-based cancer therapies. The contest will culminate at CPHI Worldwide in Frankfurt this October, spotlighting promising biotechs ready to scale their innovation.
“Despite unprecedented scientific advances, many oncology treatments still face hurdles at the funding stage,” said Julita Balcerek, PhD, COO at Mabion. “This contest is our invitation to innovators who just need the right partner. We’re offering more than a prize; we’re offering a path to impact.”
The initiative provides a simplified entry process via QR code at Mabion’s booth and on a dedicated landing page. Selected entrants will be guided through pre-qualification, NDAs, and proposal shaping with Mabion’s business development team.
An independent jury of experts will evaluate entries based on scientific merit, feasibility, and potential patient impact. The winner will receive a €500,000 credit toward Mabion’s integrated CDMO capabilities, including process and analytical development, upstream/downstream processing, and clinical supply manufacturing. Runner-up entries may also be invited into partnership discussions, reinforcing Mabion’s focus on long-term collaboration.
“Wherever you’re based, this is your chance to accelerate your breakthrough program with Mabion’s financial support and world class services,” Balcerek added. “Mabion is proud to help turn scientific ambition into clinical reality.”
The launch is supported by a multi-channel campaign featuring LinkedIn promotions, media outreach, email engagement, and in-booth activations at BIO and CPHI. Countdown content and giveaways will maintain visibility throughout the program.
More details can be found here.
